EX-99.2 3 y07877exv99w2.txt CERTAIN SUPPLEMENTAL INFORMATION Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FIRST QUARTER 2005 OTHER (INCOME)/EXPENSE, NET (millions of dollars)
1Q `05 1Q `04 ------ ------- INTEREST INCOME $(93.8) $ (65.7) INTEREST EXPENSE 84.5 72.8 EXCHANGE (GAINS)/LOSSES (0.7) (7.8) MINORITY INTERESTS 30.4 39.6 Other, net 6.1 (312.2) ------ -------- TOTAL $ 26.5 $(273.3) ------ --------
JOINT VENTURE SALES DETAIL (millions of dollars) All sales reported here are end-market JV sales, presented on a "NET" basis.
MERIAL 1Q `05 1Q `04 ------ ------ IVOMEC, HEARTGARD, other avermectins $ 117 $ 94 FRONTLINE 202 161 Biologicals 120 113 Other Animal Health 56 51 Poultry Breeding 9 9 ------ ------ TOTAL MERIAL SALES $ 504 $ 428 ------ ------
SANOFI PASTEUR-MSD 1Q `05 1Q `04 ------ ------ HEPATITIS VACCINES $ 22 $ 20 VIRAL VACCINES 17 13 Other Vaccines 131 120 ------ ------ TOTAL SANOFI-MSD SALES $ 170 $ 153 ------ ------
MERCK / SCHERING-PLOUGH COLLABORATION 1Q `05 1Q `04 ------ ------ VYTORIN (Worldwide) $ 179 $ -- ZETIA (Worldwide) 332 190 ------ ------ TOTAL $ 511 $ 190 ------ ------
MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FIRST QUARTER 2005 NET PRODUCT SALES DETAIL (millions of dollars)
1Q `05 vs. 1Q `04 ---------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ----- ----- ----- ---- ------- ------- AGGRASTAT 1% 23 N/A -- 1% 23 ARCOXIA 87% 57 N/A -- 87% 57 CANCIDAS 48% 130 37% 67 62% 63 COZAAR / HYZAAR 14% 719 8% 234 17% 485 CRIXIVAN / STOCRIN 23% 79 55% 9 19% 69 EMEND * 17 * 15 * 2 FOSAMAX 2% 772 -7% 410 14% 362 INVANZ 66% 20 48% 13 * 7 MAXALT 40% 78 61% 48 15% 30 PRIMAXIN 23% 185 86% 54 8% 131 PROPECIA 11% 70 11% 32 11% 38 PROSCAR 0% 175 -5% 79 5% 96 SINGULAIR 18% 735 16% 493 23% 242 TIMOPTIC / TIMOPTIC XE -14% 32 12% 3 -16% 29 TRUSOPT / COSOPT 7% 140 -4% 50 13% 90 VASOTEC / VASERETIC -8% 158 N/A -- -8% 158 VIOXX * -- * -- * -- ZOCOR -15% 1,106 -18% 738 -7% 368 HEPATITIS VACCINES -41% 36 -53% 24 42% 11 VIRAL VACCINES 14% 133 8% 115 64% 19 OTHER VACCINES 6% 55 -1% 39 29% 16
* 100% or over N/A - Not Applicable TOTAL SALES: VOLUME, PRICE, EXCHANGE
1Q `05 % CHG. VOL PX FX ------ ------ --- -- -- TOTAL PHARMACEUTICAL SALES $5,362 -5% -7 1 2 ------ ------ --- -- -- U.S. ($ MM) 3,017 -7% -10 3 N/A Foreign ($ MM) 2,345 -1% -3 -3 4